• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

不同分级子宫内膜癌中 VEGF-A、VEGF-B、VEGFR-1、VEGFR-2 表达谱的变化。

Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer.

机构信息

Center of Oncology, M. Sklodowska-Curie Memorial Institute, Cracow Branch, Poland.

Department of Gynecology and Obstetrics with Gynecologic Oncology, Ludwik Rydygier Memorial Specialized Hospital, Krakow, Poland.

出版信息

Curr Pharm Biotechnol. 2019;20(11):955-963. doi: 10.2174/1389201020666190717092448.

DOI:10.2174/1389201020666190717092448
PMID:31322068
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7403754/
Abstract

BACKGROUND

VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 are important proteins involved in the induction and development of a new blood vessel network through which the tumor is properly nourished and oxygenated.

OBJECTIVES

The aim of the study was to evaluate changes in VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 expression in endometrial cancer depending on its grade and to determine the VEGFR-1 to VEGFR-2 concentration ratio.

METHODS

The study group consisted of 45 patients diagnosed with endometrial cancer (G1, 17; G2, 15; G3, 13). The control group included 15 patients. VEGF-A, VEGF-B, VEGF-R1, VEGFR-2 expression was assessed using the immunohistochemical method. Statistical analysis was carried out using the Statistica 12 PL program (StatSoft, Cracow, Poland). It included the one-way ANOVA and Tukey's post-hoc test (p<0.05).

RESULTS

Statistically significant differences in the level of VEGF-A, VEGF-B, VEGF-R1, VEGFR-2 were observed between the majority of analyzed groups (except for VEGF-B; G3 vs. G1, p=0.997700). The expression pattern of VEGF-A, VEGF-R1, VEGFR-2 was as follows: G3>G2>G1>C; VEGF-B: G2> G3> G1>C. A lower concentration of VEGFR-1 than VEGFR-2 was found regardless of the cancer grade.

CONCLUSION

VEGF-A, VEGF-B, VEGF-R1, VEGFR-2 are key proteins involved in tumor angiogenesis. The analysis of the entire panel of proteins participating in a given process is an important element of modern diagnostics. The concentration ratio of VEGFR-1 to VEGFR-2 appears to be a determining factor in the patients' survival prognosis.

摘要

背景

VEGF-A、VEGF-B、VEGFR-1 和 VEGFR-2 是参与诱导和发展新血管网络的重要蛋白，肿瘤正是通过这些血管网络获得适当的营养和氧气供应。

目的

本研究旨在评估子宫内膜癌中 VEGFA、VEGF-B、VEGFR-1 和 VEGFR-2 表达的变化取决于其分级，并确定 VEGFR-1 与 VEGFR-2 的浓度比。

方法

研究组包括 45 名被诊断为子宫内膜癌的患者（G1，17 例；G2，15 例；G3，13 例）。对照组包括 15 名患者。使用免疫组织化学方法评估 VEGF-A、VEGF-B、VEGF-R1、VEGFR-2 的表达。使用 Statistica 12 PL 程序（StatSoft，克拉科夫，波兰）进行统计分析。包括单向方差分析和 Tukey 事后检验（p<0.05）。

结果

在大多数分析组之间观察到 VEGF-A、VEGF-B、VEGF-R1、VEGFR-2 的水平存在统计学显著差异（除了 VEGF-B；G3 与 G1，p=0.997700）。VEGF-A、VEGF-R1、VEGFR-2 的表达模式如下：G3>G2>G1>C；VEGF-B：G2>G3>G1>C。无论癌症分级如何，均发现 VEGFR-1 的浓度均低于 VEGFR-2。

结论

VEGF-A、VEGF-B、VEGF-R1、VEGFR-2 是参与肿瘤血管生成的关键蛋白。分析参与特定过程的整个蛋白组是现代诊断的重要组成部分。VEGFR-1 与 VEGFR-2 的浓度比似乎是患者生存预后的决定因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f7/7403754/39a5a0c8fd31/CPB-20-955_F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f7/7403754/6eb7eecbeab3/CPB-20-955_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f7/7403754/1c372f55bdf4/CPB-20-955_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f7/7403754/22e6d085b8c2/CPB-20-955_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f7/7403754/39a5a0c8fd31/CPB-20-955_F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f7/7403754/6eb7eecbeab3/CPB-20-955_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f7/7403754/1c372f55bdf4/CPB-20-955_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f7/7403754/22e6d085b8c2/CPB-20-955_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f7/7403754/39a5a0c8fd31/CPB-20-955_F4.jpg

相似文献

1
Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer.不同分级子宫内膜癌中 VEGF-A、VEGF-B、VEGFR-1、VEGFR-2 表达谱的变化。
Curr Pharm Biotechnol. 2019;20(11):955-963. doi: 10.2174/1389201020666190717092448.
2
Expression Profile of VEGF-C, VEGF-D, and VEGFR-3 in Different Grades of Endometrial Cancer.VEGF-C、VEGF-D 和 VEGFR-3 在不同分级子宫内膜癌中的表达谱。
Curr Pharm Biotechnol. 2019;20(12):1004-1010. doi: 10.2174/1389201020666190718164431.
3
Prognostic significance of VEGF and its receptors in endometrioid endometrial cancer.血管内皮生长因子及其受体在子宫内膜样腺癌中的预后意义
Ginekol Pol. 2010 Jun;81(6):422-5.
4
Differential expression of VEGF ligands and receptors in prostate cancer.血管内皮生长因子配体和受体在前列腺癌中的差异表达。
Prostate. 2013 May;73(6):563-72. doi: 10.1002/pros.22596. Epub 2012 Oct 4.
5
Glutamate Neonatal Excitotoxicity Modifies VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 Protein Expression Profiles During Postnatal Development of the Cerebral Cortex and Hippocampus of Male Rats.谷氨酸新生体兴奋毒性改变雄性大鼠大脑皮质和海马体在出生后发育过程中 VEGF-A、VEGF-B、VEGFR-1 和 VEGFR-2 蛋白表达谱。
J Mol Neurosci. 2017 Sep;63(1):17-27. doi: 10.1007/s12031-017-0952-7. Epub 2017 Jul 29.
6
Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma.血管内皮生长因子 A、血管内皮生长因子受体 1 和血管内皮生长因子受体 2 的免疫组织化学表达对经典型霍奇金淋巴瘤患者的预后意义。
Leuk Lymphoma. 2014 Mar;55(3):558-64. doi: 10.3109/10428194.2013.813629. Epub 2013 Jul 16.
7
Expression of Semaphorin 3B (SEMA3B) in Various Grades of Endometrial Cancer.Semaphorin 3B（SEMA3B）在不同分级子宫内膜癌中的表达。
Med Sci Monit. 2019 Jun 20;25:4569-4574. doi: 10.12659/MSM.916762.
8
Expression and prognostic significance of vascular endothelial growth factor-A (VEGF-A) and its receptor in canine prostate cancer.血管内皮生长因子-A（VEGF-A）及其受体在犬前列腺癌中的表达及预后意义
Prostate. 2021 Oct;81(14):1021-1031. doi: 10.1002/pros.24199. Epub 2021 Jul 28.
9
[Expression of vascular endothelial growth factor and its receptors in endometrial carcinoma].血管内皮生长因子及其受体在子宫内膜癌中的表达
Zhonghua Bing Li Xue Za Zhi. 2002 Oct;31(5):391-5.
10
Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.血管内皮生长因子（VEGF）及其受体（Flt-1和Flk-1）在食管鳞状细胞癌中的表达
Anticancer Res. 2002 Nov-Dec;22(6C):3977-84.

引用本文的文献

1
HIF1A, EPAS1, and VEGFA: angiogenesis and hypoxia-related gene expression in endometrium and endometrial epithelial tumors.缺氧诱导因子1α（HIF1A）、内皮 PAS 结构域蛋白1（EPAS1）和血管内皮生长因子 A（VEGFA）：子宫内膜及子宫内膜上皮肿瘤中的血管生成与缺氧相关基因表达
J Appl Genet. 2025 Jan 31. doi: 10.1007/s13353-025-00939-7.
2
The Pivotal Role of the Key Angiogenic Factors in the Development of Endometrioid Pathologies of the Uterus and Ovary.关键血管生成因子在子宫和卵巢子宫内膜样病变发展中的关键作用。
Cancers (Basel). 2024 Aug 6;16(16):2772. doi: 10.3390/cancers16162772.
3
Sorcin promotes proliferation of hepatocellular carcinoma by regulating VEGFA/B via PI3K pathway.

本文引用的文献

1
The Prognostic Value of the Combination of Low VEGFR-1 and High VEGFR-2 Expression in Endothelial Cells of Colorectal Cancer.结直肠癌内皮细胞中低 VEGFR-1 与高 VEGFR-2 表达的联合预后价值。
Int J Mol Sci. 2018 Nov 9;19(11):3536. doi: 10.3390/ijms19113536.
2
Changes in the Expression Profile of JAK/STAT Signaling Pathway Genes and Mirnas Regulating their Expression Under the Adalimumab Therapy.阿达木单抗治疗下JAK/STAT信号通路基因及其调控miRNA表达谱的变化
Curr Pharm Biotechnol. 2018;19(7):556-565. doi: 10.2174/1389201019666180730094046.
3
Vascular Endothelial Growth Factor B and Its Signaling.
Sorcin 通过调控 PI3K 通路促进肝癌细胞增殖。
J Physiol Biochem. 2024 May;80(2):381-392. doi: 10.1007/s13105-024-01011-4. Epub 2024 Mar 27.
4
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.AB160 纳米免疫偶联物治疗妇科恶性肿瘤的 I 期临床试验。
Clin Cancer Res. 2024 Jun 14;30(12):2623-2635. doi: 10.1158/1078-0432.CCR-23-3196.
5
Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study.子宫肉瘤和癌肉瘤的预后因素：一项 10 年随访研究的结果。
Med Sci Monit. 2023 Dec 7;29:e941562. doi: 10.12659/MSM.941562.
6
Loss of Expression of Antiangiogenic Protein FKBPL in Endometrioid Endometrial Carcinoma: Implications for Clinical Practice.血管生成抑制蛋白 FKBPL 在子宫内膜样型子宫内膜癌中的表达缺失：对临床实践的影响。
Medicina (Kaunas). 2022 Sep 22;58(10):1330. doi: 10.3390/medicina58101330.
7
Endothelial cell-specific molecule 1 (ESM1) promoted by transcription factor SPI1 acts as an oncogene to modulate the malignant phenotype of endometrial cancer.由转录因子SPI1促进的内皮细胞特异性分子1（ESM1）作为一种癌基因来调节子宫内膜癌的恶性表型。
Open Med (Wars). 2022 Aug 26;17(1):1376-1389. doi: 10.1515/med-2022-0529. eCollection 2022.
8
Decoding the mechanism of vascular morphogenesis to explore future prospects in targeted tumor therapy.解析血管形态发生机制，探索靶向肿瘤治疗的未来前景。
Med Oncol. 2022 Aug 29;39(11):178. doi: 10.1007/s12032-022-01810-z.
9
Circ 003390/Eukaryotic translation initiation factor 4A3 promoted cell migration and proliferation in endometrial cancer via vascular endothelial growth factor signaling by miR-195-5p.环状 RNA 003390/真核翻译起始因子 4A3 通过 miR-195-5p 调控血管内皮生长因子信号通路促进子宫内膜癌细胞迁移和增殖
Bioengineered. 2022 May;13(5):11958-11972. doi: 10.1080/21655979.2022.2069358.
10
Exosomes on Endometrial Cancer: A Biomarkers Treasure Trove?子宫内膜癌中的外泌体：生物标志物宝库？
Cancers (Basel). 2022 Mar 29;14(7):1733. doi: 10.3390/cancers14071733.
血管内皮生长因子B及其信号传导
Front Cardiovasc Med. 2018 Apr 20;5:39. doi: 10.3389/fcvm.2018.00039. eCollection 2018.
4
New therapies for advanced, recurrent, and metastatic endometrial cancers.晚期、复发性和转移性子宫内膜癌的新疗法。
Gynecol Oncol Res Pract. 2017 Dec 2;4:19. doi: 10.1186/s40661-017-0056-7. eCollection 2017.
5
Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients.I型和II型子宫内膜癌患者治疗前血清VEGF及其受体、IL-8水平的临床意义及其预后价值
PLoS One. 2017 Oct 9;12(10):e0184576. doi: 10.1371/journal.pone.0184576. eCollection 2017.
6
Identification of a gene expression profile associated with the regulation of angiogenesis in endometrial cancer.子宫内膜癌中与血管生成调控相关的基因表达谱鉴定。
Mol Med Rep. 2017 Sep;16(3):2547-2555. doi: 10.3892/mmr.2017.6868. Epub 2017 Jun 28.
7
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?癌症抗血管生成再探讨：与免疫疗法联合使用是否有作用？
Angiogenesis. 2017 May;20(2):185-204. doi: 10.1007/s10456-017-9552-y. Epub 2017 Mar 30.
8
Prognostic significance of combining VEGFA, FLT1 and KDR mRNA expression in lung cancer.VEGFA、FLT1和KDR mRNA表达联合检测在肺癌中的预后意义
Oncol Lett. 2015 Sep;10(3):1893-1901. doi: 10.3892/ol.2015.3415. Epub 2015 Jun 24.
9
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.美国食品药品监督管理局批准摘要：雷莫西尤单抗用于治疗铂类化疗期间或之后疾病进展的转移性非小细胞肺癌。
Oncologist. 2015 Nov;20(11):1320-5. doi: 10.1634/theoncologist.2015-0221. Epub 2015 Oct 7.
10
Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.VEGF 及其受体 VEGFR1/VEGFR2 的表达与膀胱癌的侵袭性有关。
Anticancer Res. 2013 Jun;33(6):2381-90.